Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
helen.sheldon@well.ox.ac.uk

Research groups

Church group: tumour genomics and immunology

Helen Sheldon

Senior Scientist/Lab Manager,

Recent publications

Chronic hypoxia in TNBC breast cancer induces development of a novel population of CD24+/CD49b-high cells characterized by high expression of CST1

Ke MS. et al, (2024), CANCER RESEARCH, 84

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.

de Heer EC. et al, (2023), Journal of experimental & clinical cancer research : CR, 42

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.

de Heer EC. et al, (2023), Journal of experimental & clinical cancer research : CR, 42

Single cell RNA‐sequencing: A powerful yet still challenging technology to study cellular heterogeneity

Ke M. et al, (2022), BioEssays, 44

ELTD1 is present in extracellular vesicles derived from endothelial cells as a cleaved extracellular domain which induces in vivo angiogenesis.

Sheldon H. et al, (2022), Journal of extracellular biology, 1